Qualigen obtains exclusive license to novel cancer drug technology from Advanced Cancer Therapeutics
Qualigen, Inc., and Advanced Cancer Therapeutics, LLC (ACT) today announced that Qualigen has licensed certain ACT patents, intellectual property and know-how associated with the antiproliferative activity of G-rich oligonucleotides ACT-GRO-777…